Clinical Neuroproteomics

    Clinical Neuroproteomics
    Clinical Neuroproteomics
    Identification of proteins and peptides in neuropathogenic processes

    The activity of this Unit is aimed at defining the molecular processes involved in the development of neurodegenerative diseases. In order to achieve this goal, it works on the identification of the proteins and peptides involved in the neuropathogenic processes leading to Alzheimer’s disease, Parkinson’s disease, multiple sclerosis and amyotrophic lateral sclerosis, using proteomic tools to identify and quantify hundreds of proteins in human brain cells and disease animal models. Using bioinformatics analysis, disease-specific molecular mechanisms are identified, characterising proteins with a potential prognostic and/or diagnostic value.
    The team leads the Neurological Disorders Programme, which is part of the Human Proteome Project through a Spanish consortium established by ProteoRed-Instituto de Salud Carlos III.

     

    HBPP

    Lines of research:
    • The group leads the Neurological Disorders Programme, which is part of the Human Proteome Project through a Spanish consortium established by ProteoRed-Instituto de Salud Carlos II.
    • Olfaction and neurodegeneration.
    • Characterisation of the molecular mechanisms involved in the development of neurodegenerative disease.
    • Molecular analysis of lateralisation of brain function using inter-hemispheric proteomics.
    Projects
    360º Virtual Tour
    Clinical Neuroproteomics
    Lab
    Documentation
    External collaborations
    BIOPTSENS
    Enrique
    Santamaría Martínez
    Head of the Unit
    Contact
    Clinical Neuroproteomics

    Navarrabiomed - Centro de investigación biomédica
    Complejo Hospitalario de Navarra, edificio de investigación.
    Calle Irunlarrea, 3. 31008 Pamplona, Navarra, España.